- Home
- SKYE vs NTRB Comparison
SKYE vs NTRB Comparison
Compare SKYE & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- NTRB
- Stock Information
- Founded
- SKYE 2012
- NTRB 2016
- Country
- SKYE United States
- NTRB United States
- Employees
- SKYE N/A
- NTRB N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- SKYE Health Care
- NTRB Health Care
- Exchange
- SKYE Nasdaq
- NTRB Nasdaq
- Market Cap
- SKYE 80.7M
- NTRB 84.1M
- IPO Year
- SKYE N/A
- NTRB N/A
- Fundamental
- Price
- SKYE $2.50
- NTRB $6.20
- Analyst Decision
- SKYE Buy
- NTRB Buy
- Analyst Count
- SKYE 7
- NTRB 1
- Target Price
- SKYE $18.67
- NTRB $13.00
- AVG Volume (30 Days)
- SKYE 136.3K
- NTRB 52.2K
- Earning Date
- SKYE 05-09-2025
- NTRB 04-30-2025
- Dividend Yield
- SKYE N/A
- NTRB N/A
- EPS Growth
- SKYE N/A
- NTRB N/A
- EPS
- SKYE N/A
- NTRB N/A
- Revenue
- SKYE N/A
- NTRB $2,021,771.00
- Revenue This Year
- SKYE N/A
- NTRB $7.95
- Revenue Next Year
- SKYE N/A
- NTRB $538.25
- P/E Ratio
- SKYE N/A
- NTRB N/A
- Revenue Growth
- SKYE N/A
- NTRB N/A
- 52 Week Low
- SKYE $2.31
- NTRB $2.22
- 52 Week High
- SKYE $17.65
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- SKYE 42.36
- NTRB 43.52
- Support Level
- SKYE $2.40
- NTRB $6.00
- Resistance Level
- SKYE $2.88
- NTRB $6.49
- Average True Range (ATR)
- SKYE 0.23
- NTRB 0.47
- MACD
- SKYE -0.02
- NTRB -0.15
- Stochastic Oscillator
- SKYE 18.18
- NTRB 11.43
Stock Price Comparison Chart: SKYE vs NTRB
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.